# Soligenix Inc. (NASDAQ: SNGX) Strengthens Position in CTCL Treatment with HyBryte(TM) FLASH Results

* The original FLASH study enrolled 169 patients across three treatment cycles.
* The ongoing FLASH 2 trial builds on findings found in the first study while addressing regulatory requirements for confirmatory evidence.
* For Soligenix, the FLASH studies represent more than clinical milestones. These studies are key steps in the company’s regulatory and commercial journey.

 Soligenix (NASDAQ: SNGX) is continuing to build momentum in its mission to advance HyBryte(TM), a first-in-class treatment for early-stage cutaneous T-cell lymphoma (“CTCL”). That progress is supported by results from its pivotal FLASH trial and its ongoing FLASH 2 confirmatory study. Together, the studies highlight not only the efficacy of synthetic hypericin activated by safe fluorescent light but also the company’s broader strategy to establish HyBryte as a new standard of care in a field where therapeutic innovation has lagged (https://www.ibn.fm/G18Hp). With statistically significant data already achieved and confirmatory enrollment well underway, Soligenix is taking important steps toward potential regulatory approvals Worldwide.

 The original FLASH study, the largest double-blind, randomized, placebo-controlled trial ever conducted in CTCL, enrolled 169 patients across three treatment cycles. Patients receiving HyBryte showed compelling results, with statistically significant improvements observed as early as…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/soligenix-inc-nasdaq-sngx-strengthens-position-in-ctcl-treatment-with-hybrytetm-flash-results/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/soligenix-advances-hybrytetm-for-ctcl-with-flash-trial-success/65e093601f870bbbcfef6741851a6da2) 

 



[Reddit Post](https://www.reddit.com/r/HealthCareNewsInfo/comments/1npm4h6/soligenix_advances_hybryte_for_ctcl_with_flash/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/259/24/ninaVAIb.webp)